

200.1133CON2

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner:	Not Yet Assigned	Art Unit:
Re:	Application of:	Benjamin OSHLACK, et al.
Serial No.:		Not Yet Assigned
Filed:		Herewith
For:		<b>TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS</b>

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

November 4, 2003

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Forms PTO-1449, which is a copy of the Forms submitted in connection with the parent application, US Serial No. 09/781,08, for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants also respectfully advise the Examiner of the following issued U.S. patents and co-pending U.S. patent applications which are commonly assigned to the owners of the instant application:

U.S. Patent Application Serial No. 10/244,783, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed September 16, 2002, which is a continuation application of U.S. Patent Application Serial No. 09/815,167, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed March 22, 2001, now U.S. Patent No. 6,475,494, issued on November 5, 2002, which is a continuation application of U.S. Patent Application Serial No. 09/218,662,

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

200.1133CON2

"OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued on August 21, 2001.

U.S. Patent Application Serial No. 09/992,936, "OPIOID AGONIST/OPIOID ANTAGONIST/ACETAMINOPHEN COMBINATIONS", filed November 5, 2001, which is a continuation application of U.S. Patent Application Serial No. 09/503,020, "OPIOID AGONIST/OPIOID ANTAGONIST/ACETAMINOPHEN COMBINATIONS", filed February 11, 2002, now U.S. Patent No. 6,375,957, issued on April 23, 2002, which is a continuation-in-part of U.S. Patent Application Serial No. 09/218,662, "OPIOID AGONIST/ANTAGONIST COMBINATIONS", filed December 22, 1998, now U.S. Patent No. 6,277,384, issued on August 21, 2001.

U.S. Patent Application Serial No. 09/815,162, "METHOD OF PREVENTING ABUSE OF OPIOID DOSAGE FORMS", filed March 22, 2001, which is a continuation application of U.S. Patent Application Serial No. 09/218,663, "METHOD OF PREVENTING ABUSE OF OPIOID DOSAGE FORMS", filed December 22, 1998, now U.S. Patent No. 6,228,863, issued on May 8, 2001.

U.S. Patent Application Serial No. 09/781,076, "CONTROLLED-RELEASE COMPOSITIONS CONTAINING OPIOID AGONIST AND ANTAGONIST", filed February 8, 2001, pending.

U.S. Patent Application Serial No. 10/199,972, "PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE", filed July 18, 2002, pending.

U.S. Patent Application Serial No. 10/213,919, "OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTERED ANTAGONIST", filed August 6, 2002, pending.

U.S. Patent Application Serial No. 10/214,408, "SEQUESTERED ANTAGONIST FORMULATIONS", filed August 6, 2002, pending.

U.S. Patent Application Serial No. 10/213,921, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND BITTERING AGENT", filed August 6, 2002, pending.

U.S. Patent Application Serial No. 10/214,409, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST, AND IRRITANT", filed August 6, 2002, pending.

U.S. Patent Application Serial No. 10/214,413, "PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT", filed August 6, 2002, pending.

Pursuant to 37 C.F.R. § 1.98 (a)(2)(iii) the Examiner's attention is directed to Exhibit A attached herewith which contains the following:

- (i) specifications and claims for pending application serial nos. 09/781,076; 10/199,972; 10/213,919; 10/214,408; and 10/213,921;
- (ii) claims of pending application serial no. 10/244,783, which has the same specification as U.S. Patent No. 6,277,384, listed as reference AB on the Form PTO 1449 submitted with the Information Disclosure Statement of November 7, 2001;
- (iii) claims of pending application serial no. 09/992,936, which has the same specification as U.S. Patent No. 6,375,957, listed as reference LD on enclosed Form PTO-1449;

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

(iv) claims of pending application serial no. 09/815,162, which has the same specification as U.S. Patent No. 6,228,863, listed as reference AA on the Form PTO 1449 submitted with the Information Disclosure Statement of November 7, 2001;

(v) claims of pending application serial nos. 10/214,413; and 10/214,409, which have the same specification as that of application serial no. 10/213,921, mentioned above in paragraph (i).

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due. However, if it is determined that any additional fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:   
Robert J. Paradiso  
Reg. No. 41,240

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 Seventh Avenue, 14th Floor  
New York, New York 10018  
(212) 736-1940

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.						
								FILING DATE: February 8, 2001		GROUP: 1615				
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	AA	3	0	0	5	2	0	0	06/22/1976	Leslie	424	22		
	AB	4	2	3	1	1	4	0	12/02/1980	Dudzinski	424	260		
	AI	4	3	0	5	3	1	0	12/28/1982	Leslie	536	56		
	AD	4	4	4	3	4	2	8	04/17/1984	Oshlack, et al.	424	22		
	AE	4	0	2	8	0	3	0	05/09/1989	Eiger, et al.	424	465		
	AF	4	8	3	4	0	8	5	05/30/1989	Martani, et al.	424	488		
	AI	4	5	3	1	1	4	4	05/30/1989	Goldie, et al.	424	488		
	AI	4	4	3	1	3	0	5	05/30/1989	Eiger, et al.	424	488		
	AI	4	5	4	4	0	0	2	07/04/1989	Eiger, et al.	424	465		
	AI	4	4	4	4	0	0	9	07/04/1989	Goldie, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
												YES	NO	
	AB	0	1	0	3	3	0	0	09/03/1986	Europe (A3)	A61K	31/615		
	AL	4	3	4	3	2	4	3	06/07/1989	Europe (A1)	A61K	31/485		
	AI	0	3	2	0	9	4	3	11/07/1990	Europe (A2)	A61K	31/485		
	AN	0	0	0	1	3	4	7	01/13/2000	WO	A61K	31/00		
	AD	0	0	0	1	9	0	0	05/17/1990	WO	A61K	31/485		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	AP	Translation of previously submitted German patent application DE 43 25 465												
	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205												
	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663												
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. ./J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/761,081	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.		
						FILING DATE: February 5, 2001	GROUP: 1615	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
BA		4 8 4 4 0 4 0	07/04/1989	Leslie, et al.	424	494		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
BB							YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9						
	BS	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine", Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429						
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications", NIDA Research Monograph 147 (1995) pg. 53-83						
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20", 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349						
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213						
	BF	Briscoe, et al., "Methoclocimamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399						
	BF	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551						
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs", Clinical Pharm. (1983) 8: 332-343						
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Ther (1974) Vol. 15, No. 6 pg. 556-564						
	BF	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F						
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May 51 (5) pg. 713-737						
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8						
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Ther (1984) Vol. 36, No. 5, pg. 704-708						
	BF	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360						
	BO	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280						
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED			06/08/2008	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.						
						FILING DATE: February 8, 2001	GROUP: 1615					
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS				
	CA	4	8	6	7	8	6	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
	CA								YES	NO		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11										
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131										
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5, pg. 568-577										
	CF	Fishman, et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580										
	CC	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386										
	CH	Freye, et al., "Effects of Tramadol and Tiliidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (1) (2000) pg. 24-30										
	CI	Fudala, et al., "Effects of Buprenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8										
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefone"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306										
	CA	Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefone"; Clin Pharmacol Ther. (1986) pg. 537-542										
	CC	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41										
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113										
	CN	Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197										
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647										
	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting Mu Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236										
EXAMINER /James Alstrum Acevedo/						DATE CONSIDERED 06/08/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshlack, et al.			
						FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
DB		4 9 4 0 9 8 7	07/10/1990	Jenkins, et al.	424	480			
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
DB							YES	NO	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
DC	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39								
DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzniem-Forsch/Drug Res. 35 (No 11) (1985) pg. 1742-1744								
DK	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135								
DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176								
DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257								
DK	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846								
DK	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174								
DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211								
DK	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458								
DC	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209								
DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242								
DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993								
DL	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383								
DK	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634								
DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages								
DK	Umbreit, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190								
EXAMINER /James Alstrum Acevedo/					DATE CONSIDERED 06/08/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT(S): Oshlack, et al.		
					FILING DATE: February 5, 2001	GROUP: 1615	
U.S. PATENT DOCUMENTS							
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA		0 0 7 0 0 7 0	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
EB							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EE	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034						
ED	Wang, et al., "Inverse agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600						
EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261						
EE	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342						
EG	Wells, et al., "In Vivo Pharmacological Characterization of SOR 9409, a Nonpeptidic Opioid $\mu$ -Agonists/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605						
EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6						
EI	Wright, et al., "Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148						
EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336						
EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209						
EE	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445						
EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94						
EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630						
EO	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385						
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 06/08/2008			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

11/4/2003

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.			
									FILING DATE: February 8, 2001	GROUP: 1615		
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FB		4	9	2	4	4	3	9	01/22/1991	Kreek, et al.	514	282
FB		4	9	9	2	3	4	4	02/05/1991	Goldie, et al	424	484
FB		6	2	2	1	2	1	3	12/10/1991	Malkowska, et al.	424	497
FD		6	9	9	1	1	9	2	02/25/1992	Heafield, et al.	424	457
FE		6	2	1	5	2	9	8	06/01/1993	Krishnamurthy	424	497
FI		6	2	2	2	3	3	1	07/13/1993	Thompson, et al.	73	865.9
FG		6	2	6	6	3	3	1	11/30/1993	Oshlack, et al.	424	497
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
FI										YES	NO	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
FI	Budd, Keith, "Clinical use of Opioid Antagonists", Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011											
FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment", Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544											
FK	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic", NIDA Research (1979) pg. 99-105											
FB	Leeeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man", Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653											
FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet", Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152											
FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats", (1987) Vol 36, pg. 127-130											
FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone", J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426											
FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans", Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37											
FC	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects", J. of Pharm and Exper Thera (1992) Vol 260, No. 1, pg. 355-363											
FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study", Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909											
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.					
									FILING DATE: February 8, 2001		GROUP: 1615			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
GA		5	2	8	8	4	9	3	02/15/1994	Oshlack, et al.	424	456		
GF		5	3	2	1	3	5	1	06/28/1994	Oshlack, et al.	106	153		
GF		5	3	8	6	8	9	1	08/09/1994	Raffa, et al.	514	629		
GF		5	3	8	6	8	6	1	10/18/1994	Oshlack, et al.	106	153		
GF		5	4	1	1	7	8	5	05/02/1995	Oshlack, et al.	424	456		
GF		5	1	8	0	8	2	8	10/24/1995	Merrill, et al.	424	470		
GG		5	1	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
GH		8	2	0	1	2	8	2	03/12/1987	WO	A61K	31/485		
GF		5	1	8	2	7	8	0	05/10/2001	WO (A2)	A61K	31/485		
GF		5	1	8	8	6	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<p>GN Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34</p> <p>GL Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151</p> <p>GM Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78</p> <p>GN Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672</p> <p>GM Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence", Anesth Analg (1997) Vol 84, pg. 810-815</p> <p>GP Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352</p> <p>GQ Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577</p>														
EXAMINER /James Alstrum Acevedo/								DATE CONSIDERED 06/08/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.				
									FILING DATE: February 8, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HA		5	6	7	8	5	2	2	12/26/1995	Sackler, et al.	424	489	
HA		5	5	6	0	2	2	2	03/19/1996	Oshlack, et al.	424	489	
HC		5	5	6	3	6	6	2	04/16/1996	Oshlack, et al.	424	468	
HD		5	5	0	8	6	6	3	04/16/1996	Krishnamurthy	424	489	
HF		5	5	0	8	0	6	2	08/27/1996	Oshlack, et al.	424	468	
HF		5	5	5	2	0	2	2	09/03/1996	Gauthier, et al.	514	368	
HG		5	5	6	1	6	5	2	01/07/1997	Miller, et al.	424	468	
HH		5	6	6	1	6	6	5	02/11/1997	Buxton, et al.	424	468	
HF		5	6	2	2	7	2	2	04/22/1997	Knott, et al.	424	494	
HJ		5	6	3	9	4	2	6	06/17/1997	Oshlack, et al.	424	468	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	HK												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HR		Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160											
HM		Martin, et al., "Bioavailability Investigation of a New Tildine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim-Forsch./Drug Res. (1999) Vol 49, pg. 599-607											
HN		Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442											
HO		Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46											
HM		Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101											
HO		Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166											
HR		Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948											
EXAMINER /James Alstrum Acevedo/									DATE CONSIDERED 06/08/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

11/4/2003

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.			
									FILING DATE: February 8, 2001	GROUP: 1615		
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
IB		5	5	5	4	9	5	08/12/1997	Oshlack, et al.	424	468	
IB		5	8	7	5	1	7	2	09/30/1997	Buxton, et al.	424	495
IC		5	8	7	2	8	8	0	09/30/1997	Sackler, et al.	424	490
ID		5	6	5	1	5	8	8	10/28/1997	Oshlack, et al.	424	494
IE		5	7	5	4	4	5	4	06/09/1998	Miller, et al.	514	282
IB		5	7	8	4	4	7	4	07/14/1998	Kim	514	282
IC		5	5	1	1	1	2	4	09/22/1998	Krishnamurthy	424	498
IH		5	4	5	5	4	7	4	11/10/1998	Mioduszewski	514	282
IH		5	4	5	4	5	4	4	12/01/1998	Miller, et al.	424	498
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO
IH												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
IK		Parwarikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354										
IL		Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of <i>Kappa</i> Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508										
IM		Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490										
IN		Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823										
IO		Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34										
IK		Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149										
IO		Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20										
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.			
									FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JF		5	§	4	5	1	4	4	12/15/1998	Miller, et al.	264	464
JB		5	§	1	9	0	4	7	02/09/1999	Wong, et al.	424	473
JD		5	§	4	5	1	4	5	04/06/1999	Heafield, et al.	424	464
JD		5	§	4	1	4	4	1	04/06/1999	Miller, et al.	424	464
JD		5	§	0	§	3	4	5	04/06/1999	Miller, et al.	514	282
JF		5	§	5	§	4	5	7	09/28/1999	Oshlack, et al.	424	457
JG		5	§	1	3	4	5	5	09/28/1999	Chasin, et al.	424	490
JI		5	§	§	5	1	6	1	10/12/1999	Oshlack, et al.	424	457
JI		5	§	§	5	1	§	4	10/12/1999	Miller, et al.	424	468
JI		5	§	6	§	5	5	1	12/15/1998	Oshlack, et al.	424	456
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO	
	JI											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	JF	Zaks, et al., "Naloxone Treatment of Opiate Dependence", JAMA (1971) Vol 215, No. 13, pg. 2108-2110										
	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics", Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58										
	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction", Current Psychiatric Therapies (1976) pg. 209-213										
	JD	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade", Inter. J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529										
	JP	Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)", Drug Addiction (1977) pg. 197-258										
	JD	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence", Substance Use Disorders (2000) pg. 519-526										
	JR	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans", Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217										
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.			
									FILING DATE: February 8, 2001	GROUP: 1615		
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
KP		5	0	2	5	6	5	02/15/2000	Oshlack, et al.	424	476	
KB		8	0	8	1	8	5	05/30/2000	Leslie, et al.	424	457	
KC		8	0	7	2	1	1	06/20/2000	Malkowska, et al.	424	457	
KD		8	5	2	2	5	3	06/20/2000	Oshlack, et al.	424	461	
KB		6	1	5	3	2	1	08/15/2001	Simon	424	449	
KB		8	3	5	3	2	5	08/15/2001	Chasin, et al.	424	459	
KG		8	1	4	1	1	2	01/07/2000	Sackler, et al.	424	459	
KH		8	1	1	3	1	2	01/07/2000	Heafield, et al.	424	459	
KC		8	1	5	2	4	8	12/19/2000	Miller, et al.	424	457	
KJ		8	2	1	0	2	1	04/03/2001	Oshlack, et al.	424	476	
KP		8	2	5	5	8	8	07/03/2001	Miller, et al.	424	468	
KL		8	2	8	1	5	6	07/17/2001	Oshlack, et al.	424	457	
KM		8	2	8	1	1	6	09/25/2001	Oshlack, et al.	424	457	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO	
KN		5	5	3	7	2	8	5	05/31/2001	WO (A2)	A61K	
KO		0	1	5	2	8	5	1	09/25/2001	WO (A1)	A61K	31/485
KP		0	1	8	5	2	5	2	11/15/2001	WO (A2)	A61K	
KQ		0	1	5	3	8	5	2	12/13/2001	WO (A2)	A61K	31/00
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans", Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82											
KS	Brennsehld, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tiliidine/Naloxone Solution or Tiliidine/Naloxone Sustained Release Tablets", Arzneim -Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022											
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.				
								FILING DATE: February 8, 2001			GROUP: 1615	
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
LA		6	6	6	8	4	4	8	10/23/2001	Oshlack, et al.	424	408
LB		6	3	2	2	0	2	2	12/04/2001	Miller, et al.	424	468
LC		6	6	3	5	0	3	5	01/01/2002	Oshlack, et al.	424	400
LD		6	4	7	8	6	5	7	04/23/2002	Kaiko, et al.	424	400
LI		6	3	6	7	4	6	3	05/14/2002	Oshlack, et al.	424	480
LI		6	3	6	5	0	6	5	05/14/2002	Miller, et al.	424	464
LG		6	4	7	8	6	6	4	11/05/2002	Kaiko, et al.	424	400
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
LI										YES	NO	
LI												
LI												
LK												
LI												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
LM												
LN												
LD												
LC												
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S): Curtis Wright et al.											
		FILING DATE: February 8, 2001				GROUP: 1615							
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA		5	9	8	8	4	1	4	12/99	Mitch et al.	514	210.16	
AB		5	9	7	7	8	8	4	12/99	Foss	514	282	
AC		5	9	5	8	8	4	7	12/99	Reder et al.	424	449	
AD		5	9	4	2	7	4	1	2/99	Chasin et al.	424	426	
AE		5	9	8	0	1	1	7	3/99	Hill	514	282	
AE		5	9	8	5	1	5	4	2/99	Kuczynski et al.	424	472	
AG		5	9	5	5	5	8	0	1/99	Demopoulos et al.	604	49	
AE		5	9	8	8	0	1	7	1/99	Demopoulos et al.	604	890.1	
AE		5	7	8	7	1	7	5	6/98	Crain et al.	514	282	
AJ		5	9	1	1	7	5	8	6/98	Qin et al.	514	282	
AB		5	9	7	4	8	1	7	4/97	Qin et al.	514	282	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER					DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION	
												YES	NO
AE		19	6	5	1	5	5	1	6/98	DE	A61K	31/485	
AM		29	7	1	8	7	C	4	2/97	DE	A61K	31/485	
AN		4	3	7	8	4	C	8	2/95	DE	A61K	31/485	X
AC		2	7	2	2	C	1	i	11/72	DE	A61K	27/00	
AE		5	9	1	1	1	8	7	2/99	EP	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	AQ	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.											
	AE	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.											
	AS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patent-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.											
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Curtis Wright et al.							FILING DATE: February 8, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
BA		5	2	7	8	2	2	7	4/97	Khanna et al.	514	399	
BA		5	5	8	0	3	4	8	12/96	Crain et al.	514	12	
BL		5	5	8	0	6	7	6	12/96	Crain et al.	514	282	
BD		5	5	2	8	7	2	5	11/96	Portoghesi et al.	546	35	
BL		5	5	7	4	2	0	2	11/96	Rose et al.	514	343	
BF		5	5	5	0	2	3	6	9/96	Mayer et al.	514	25	
BL		5	5	3	4	4	0	2	7/96	Aston et al.	514	608	
BL		5	5	4	4	2	2	0	9/96	Weber et al.	514	249	
BL		8	5	4	2	0	7	8	9/96	Crain et al.	514	282	
BL		5	5	0	2	0	8	6	9/96	Mayer et al.	514	249	
BK		8	0	8	5	3	2	2	8/98	Kitchell et al.	424	426	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
BL		0	5	8	2	8	4	8	4/95	EP	A61K	31/485	
BM		0	3	0	2	3	6	4	1/90	EP	A61K	31/485	
BN		0	2	0	0	2	6	2	12/86	EP	A61K	9/22	
BD		8	5	3	2	4	2	0	8/98	WO	A61K	31/485	
Bt		5	0	3	0	0	7	8	8/98	WO	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
BQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.												
BR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.												
EXAMINER /James Alstrum Acevedo/								DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)								APPLICANT(S): Curtis Wright et al.					
								FILING DATE: February 8, 2001		GROUP: 1615			
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CB		5	4	2	2	5	4	3	12/95	Crain et al.	514	12	
CB		5	4	5	2	2	0	0	12/95	Portoghesi et al.	546	35	
CF		5	4	2	0	1	1	2	6/95	Zagon et al.	514	282	
CD		0	0	7	6	0	0	2	10/94	Ockert	514	282	
CE		5	0	5	0	0	0	0	10/94	Bihari et al.	514	282	
CF		5	3	5	2	6	5	3	10/94	Mayer et al.	514	289	
CF		5	3	5	2	5	0	0	10/94	Portoghesi et al.	514	279	
CF		5	3	2	1	0	1	2	6/94	Mayer et al.	514	25	
CI		5	3	1	2	0	2	2	5/94	Borsodi et al.	514	282	
CJ		5	3	1	5	2	5	5	5/94	Rose et al.	424	18	
CK		5	2	2	3	2	6	0	12/93	Oshlack et al.	424	486	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
CF		9	2	3	3	5	6	6	3/94	WO	A61K	9/22	
CM		5	5	5	2	2	5	1	2/95	WO	A61K	31/485	
CN		0	5	0	3	0	0	4	2/95	WO	A61K	31/485	
CD		5	4	0	6	4	7	6	3/94	WO	A61K	31/46	
CF		0	0	0	1	0	2	9/83	WO	A61K	9/22		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	CQ	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.											
	CR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).											
EXAMINER /James Alstrum Acevedo/								DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Curtis Wright et al.				
								FILING DATE: February 8, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS												
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
DB		5	7	5	6	8	6	5	10/93	Askanazi et al.	514	282
DB		5	3	3	6	7	7	3	8/93	Lee et al.	424	449
DH		5	7	7	5	4	4	C	7/93	London et al.	514	535
DG		5	3	3	3	5	3	1	3/92	Granger et al.	424	449
DE		5	7	6	7	8	3	3	4/92	Goldberg	514	282
DH		5	0	5	6	7	7	5	3/92	Sinclair	424	449
DG		5	0	8	6	C	5	8	2/92	Sinclair et al.	514	282
DH		5	0	7	4	3	3	7	12/91	Mendelson et al.	514	282
DH		4	5	3	5	4	2	8	8/95	Lewis	514	282
DJ		4	8	6	3	3	8	C	12/89	Rzeszotarski et al.	514	282
DK		3	8	8	7	3	3	1	11/89	Sinclair	514	282
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO
DH												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
DM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.											
DN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.											
DO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.											
DP	Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ, 2120-2121.											
DQ	Foss et al., J. Clin Pharmacol (1993), 33:747-751.											
EXAMINER /James Alstrum Acevedo/						DATE CONSIDERED 06/08/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Curtis Wright et al.				
								FILING DATE: February 8, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS												
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
EB		4	0	7	3	0	7	0	10/89	Fishman et al.	412	10
EB		4	0	0	4	7	8	4	3/89	Goldberg	514	282
EC		4	0	0	4	5	9	0	3/89	Oshlack et al.		
ED		4	0	0	6	5	5	8	2/89	Wuest et al.	514	381
EH		4	8	0	5	5	4	8	2/89	Choi	514	464
EF		4	8	0	0	3	4	1	2/89	Chien et al.	424	448
EC		4	0	0	3	7	0	0	3/88	Pasternak	514	282
EH		4	7	0	5	0	0	0	11/88	Kreek et al.	514	282
EH		4	7	0	0	3	7	7	3/88	Kreek et al.	514	282
EJ		4	7	0	0	0	0	0	3/88	Rzeszotarski et al.	514	282
EB		4	7	3	0	0	4	0	3/88	Portoghesi et al.	546	10
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO
	EH											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	EH	Holmes et al., Anesth. Analg. (1993), 77:1166-73.										
	EH	Miaskowski et al., Brain Research (1992), 596:41-45.										
	EO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans." Drug and Alcohol Dependence (1992), 30:263-274.										
	EB	Cappel et al., Pharma. Biocb. & Behav. (1989), 34:425-427.										
	EO	Vaccarino et al., Pain (1989), 36:103-109.										
	EO	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence." Drugs (1988), 35:192-213.										
EXAMINER /James Alstrum Acevedo/								DATE CONSIDERED 06/08/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Curtis Wright et al.				
								FILING DATE: February 8, 2001		GROUP: 1615		
U.S. PATENT DOCUMENTS												
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FB		4	7	1	6	7	7	6	4/86	Goldberg	514	282
FB		9	6	6	1	9	9	7	4/87	Lewis et al.	514	282
FI		4	6	6	5	3	7	6	6/86	Pasternak	514	282
FD		4	6	6	7	9	3	6	4/86	Lewis et al.	514	282
FB		9	9	7	3	9	3	6	3/86	Chen et al.	604	280
FF		4	4	6	4	3	7	6	8/84	Hussain et al.	424	280
FG		9	4	6	7	9	3	3	8/84	Gordon et al.	424	280
FI		4	4	6	1	4	7	6	8/84	Ganti	424	280
FI		9	4	6	1	9	7	7	8/83	Portoghesi et al.	424	280
FJ		4	4	7	5	7	8	6	11/79	Goldberg	424	280
FB		3	3	6	6	3	4	6	6/76	Pachter et al.	424	280
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO
	FI											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	FM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.										
	FI	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.										
	FD											
	FP											
	FQ											
	FR											
EXAMINER /James Alstrum Acevedo/								DATE CONSIDERED 06/08/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A./

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S): Curtis Wright et al.										
		FILING DATE: February 8, 2001							GROUP: 1615			
		U.S. PATENT DOCUMENTS										
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
GB		9	8	7	5	5	5	Pachter et al.	424	260		
GB		5	7	7	9	5	5	Pachter et al.	424	260		
GC		3	5	7	5	5	5	Lachman et al.	424	260		
GD		5	9	9	3	6	5	Lewenstein et al.	424	260		
GE		5	9	9	7	5	5	Q	7/67	Blumberg et al.	260	285
GF		3	7	7	7	5	5	9	11/56	Fronherz et al.	167	65
GI												
GH												
GI												
GJ												
GI												
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
GI										YES	NO	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
GM												
GN												
GO												
GP												
GQ												
GR												
GS												
EXAMINER /James Alstrum Acevedo/							DATE CONSIDERED 06/08/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A./

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. D.  
200.1133ET NO.:  
SERIAL NO.: 09/781,081

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8,  
2001

GROUP: 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		AA	6	2	2	8	8		Palermo et al.	514	282		
	AB	6	2	7	7	3	8	4	Kaiko et al.	424	400		

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>	
		AC	WO	98	2	5	6		EPO	A61K	31/485	Abstract	
	AD	WO	00	3	8	6	4	9	07/06/00	EPO	A61K	9/00	Abstract

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001.
AF	Paronis, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats, J Pharm. Exper. Ther. 1991 259(2) pg 582-589
AG	Yoburn, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539
AH	Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82
AI	Zhang, et al., Down-Regulation of $\mu$ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240
AJ	Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694
AK	Di Giannuario, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 183-186
AL	Cicciolioppo, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphine, Eur. J. Pharmacol. 2000 404, pg 153-159
AM	
AN	

EXAMINER James Alstrum Acevedo/ 06/08/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.A./

11/4/2003

Sheet 1 of 1

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Curtis WRIGHT, et al.		
				FILING DATE: February 8, 2001		GROUP: 1615
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS
					TRANSLATION	
					YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AA	Benfey, Function of Myocardial $\alpha$ -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112					
AB	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
AC	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) [Publication Date]: Brain Research Bulletin, Vol. 33 pg 237-240					
A#	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a $\mu$ , $\delta$ or $\kappa$ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
A#	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38					
AF	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79					
AG	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER	James Alstrum Acevedo/		DATE CONSIDERED			
06/08/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.H.A.